Drug Information Association Logo
« Back to Listing

Improving Returns on Invested Capital in the Pharmaceutical and Biotechnology Industry

Track:
Project/Portfolio Management and Strategic Planning

Day & Time:
June 16, 11:00AM - 12:30PM (Pacific Standard Time)

Session Number:
125

Room Number:
5A

Level:
Advanced

Type:
Session

Title:
Improving Returns on Invested Capital in the Pharmaceutical and Biotechnology Industry

Chair(s):
Akhil Agrawal, PhD, MBA, PMP
Associate Director
Janssen Pharmaceutical Companies of Johnson & Johnson, United States

Description:
This session will focus on sharing best practices when adapting to the changing health care environment and improving the value of R&D projects. Presentations including case studies will be provided followed by an open forum discussion.

Learning Objective(s):
Discuss how to adapt to changing circumstances to improve the return on invested capital (ROIC) for R&D projects; Describe broader trends such as the changing health care environment, more influential small biotech (including virtual firms) and CROs, and importance of global strategies.

Presentation(s) & Speaker(s):
Early Commercialization: It’s More Than Just Early Input from Marketing
Alan C. Crowther
Chief Executive Officer
Alliance Life Sciences, United States

Key Cost Drivers in Clinical Trials
Frank J. Cattie
Vice President, Trial Planning Solutions
Medidata Solutions, United States

Maximizing the Value of Licensed Drug: Blending Science with Commercial Assessment and Contemporary Funding Models
Richard N Williams, JD, PhD
Senior Director Global Regulatory Strategy
Covance Inc., United States